Submitted by: Submitted by Marketreport
Views: 10
Words: 605
Pages: 3
Category: Business and Industry
Date Submitted: 06/13/2016 09:59 PM
Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!
Browse Detail Report With TOC @
https://marketreportscenter.com/reports/139675/rising-stars-outlook-2016-new-emergence-of-potential-tx-dx-options-could-transform-the-current-landscape-for-liver-diseases-nash
Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.
Table Of Content
1. Conatus Pharmaceuticals (CNAT)
-
Emricasan: Disease Modifying Potential across the Spectrum of Liver Diseases
- KEY MILESTONES (CNAT)
- 2. Trends in overall population driven by significant improvement in MELD ?15 subgroup
Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTH
- Table 1
Conatus Pharma
PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES
- Table 2
Conatus Pharma
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
- Figure 3...